Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide. (2nd November 2021)

• Record Type: Journal Article
• Authors: Lawn, Joy E; Chandna, Jaya; Paul, Proma; Jit, Mark; Trotter, Caroline; Lambach, Philipp; Ter-Meulen, Ajoke Sobanjo
• Is Part Of: Clinical infectious diseases. Volume 74(2022)Supplement 1
• Page Start: S1
• Page End: S4
• Publication Date: 2021-11-02
• Subjects: Group B Streptococcus -- maternal vaccines -- neurodevelopmental impairment -- vaccine readiness -- vaccine market shaping; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab859
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: The global burden of Group B Streptococcus (GBS) was estimated for 2015 prompting inclusion of GBS as a priority in the Global Meningitis Roadmap. New estimates for the year 2020 and a WHO report analysing the full value of GBS maternal vaccines has been launched to advance evidence based decision making for multiple stakeholders. In this first of a 10-article supplement, we discuss the following (1) gaps in evidence and action, (2) new evidence in this supplement, and (3) what actions can be taken now and key research gaps ahead. We call for investment in the research pipeline, notably description, development, and delivery, in order to accelerate progress and address the large burden of GBS for every family in every country.